Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. The trade was a 14.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $12.53 on Friday. The business’s fifty day moving average price is $11.68 and its 200 day moving average price is $11.32. The firm has a market capitalization of $9.27 billion, a PE ratio of 2.22 and a beta of 1.24. Roivant Sciences Ltd. has a 1-year low of $8.61 and a 1-year high of $13.06.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in ROIV. Vanguard Group Inc. lifted its stake in shares of Roivant Sciences by 14.6% in the first quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after purchasing an additional 1,030,681 shares during the period. Acadian Asset Management LLC purchased a new position in Roivant Sciences in the first quarter valued at about $72,000. American International Group Inc. increased its holdings in Roivant Sciences by 7,589.5% in the first quarter. American International Group Inc. now owns 450,065 shares of the company’s stock valued at $4,744,000 after buying an additional 444,212 shares in the last quarter. Magnetar Financial LLC acquired a new stake in shares of Roivant Sciences during the 1st quarter valued at approximately $1,576,000. Finally, Tyro Capital Management LLC boosted its stake in shares of Roivant Sciences by 11.1% during the 1st quarter. Tyro Capital Management LLC now owns 1,495,594 shares of the company’s stock worth $15,764,000 after acquiring an additional 149,613 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.